Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
UCB price target lowered to EUR 106 from EUR 111 at Societe Generale » 13:52
06/27/22
06/27
13:52
06/27/22
13:52
UCBJY

UCB

$42.91 /

-0.19 (-0.44%)

Societe Generale analyst…

Societe Generale analyst Florent Cespedes lowered the firm's price target on UCB to EUR 106 from EUR 111 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
UCBJY UCB
$42.91 /

-0.19 (-0.44%)

UCBJY UCB
$42.91 /

-0.19 (-0.44%)

06/27/22 UBS
UCB price target lowered to EUR 87 from EUR 95 at UBS
06/07/22 Deutsche Bank
UCB price target lowered to EUR 90 from EUR 95 at Deutsche Bank
05/20/22 Berenberg
UCB price target lowered to EUR 120 from EUR 122 at Berenberg
05/19/22 Morgan Stanley
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
Recommendations
UCB price target lowered to EUR 87 from EUR 95 at UBS » 13:50
06/27/22
06/27
13:50
06/27/22
13:50
UCBJY

UCB

$42.91 /

-0.19 (-0.44%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe lowered the firm's price target on UCB to EUR 87 from EUR 95 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
UCBJY UCB
$42.91 /

-0.19 (-0.44%)

UCBJY UCB
$42.91 /

-0.19 (-0.44%)

06/07/22 Deutsche Bank
UCB price target lowered to EUR 90 from EUR 95 at Deutsche Bank
05/20/22 Berenberg
UCB price target lowered to EUR 120 from EUR 122 at Berenberg
05/19/22 Morgan Stanley
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
05/16/22 UBS
UCB price target lowered to EUR 95 from EUR 105 at UBS
Recommendations
UCB price target lowered to EUR 90 from EUR 95 at Deutsche Bank » 12:19
06/07/22
06/07
12:19
06/07/22
12:19
UCBJY

UCB

$43.49 /

-0.165 (-0.38%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on UCB to EUR 90 from EUR 95 and keeps a Hold rating on the shares.

ShowHide Related Items >><<
UCBJY UCB
$43.49 /

-0.165 (-0.38%)

UCBJY UCB
$43.49 /

-0.165 (-0.38%)

05/20/22 Berenberg
UCB price target lowered to EUR 120 from EUR 122 at Berenberg
05/19/22 Morgan Stanley
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
05/16/22 UBS
UCB price target lowered to EUR 95 from EUR 105 at UBS
03/03/22 Morgan Stanley
UCB upgraded to Overweight from Equal Weight at Morgan Stanley
Over a month ago
Hot Stocks
UCB announces data from two Phase 3 Bimekizumab studies » 12:15
05/23/22
05/23
12:15
05/23/22
12:15
UCBJY

UCB

$45.89 /

-1.1 (-2.34%)

UCB announced detailed…

UCB announced detailed results from two Phase 3 studies which evaluated the efficacy and safety of bimekizumab versus placebo in the treatment of adults with active psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naive and in adults who had an inadequate response or intolerance to tumor necrosis factor inhibitors. The safety and efficacy of bimekizumab in psoriatic arthritis have not been established, and it is not approved for use in psoriatic arthritis by any regulatory authority worldwide. Both studies met their primary endpoint of ACR50 at week 16 and all ranked secondary endpoints compared with placebo with statistical significance. At week 16, patients treated with bimekizumab achieved clinically relevant improvements over placebo in both joint and skin symptoms with efficacy outcomes consistent across both biologic-naive and TNF-inadequate responder populations. In addition, at week 16, over 40 percent of patients in both studies achieved a minimal disease activity response compared with placebo. The adverse event profile of bimekizumab was consistent with those seen in previous studies The results will be presented at the European Congress of Rheumatology, EULAR 2022, in Copenhagen, Denmark, June 1-4. Data from BE COMPLETE and BE OPTIMAL: Joint Symptoms: In both studies, patients treated with bimekizumab achieved statistically significant improvements in the primary endpoint of at least 50 percent or greater improvement from baseline in the American College of Rheumatology response criteria at week 16, compared with placebo. In BE OPTIMAL, at week 16, 43.9 percent of biologic naive patients treated with bimekizumab achieved ACR50 versus 10.0 percent of patients on placebo; pless than0.001.1 In BE COMPLETE, at week 16, 43.4 percent of TNF-inadequate responder patients treated with bimekizumab achieved ACR50 versus 6.8 percent of patients on placebo; pless than0.001. Skin Symptoms: In both studies, patients treated with bimekizumab achieved statistically significant improvements in levels of skin clearance, as measured by the ranked secondary endpoint of at least a 90 percent improvement in the Psoriasis Area and Severity Index at week 16, compared with placebo. In BE OPTIMAL, at week 16, 61.3 percent of biologic naive patients treated with bimekizumab achieved PASI90 versus 2.9 percent on placebo; pless than0.001. In BE COMPLETE, at week 16, 68.8 percent of TNF-inadequate responder patients treated with bimekizumab achieved PASI90 versus 6.8 percent on placebo; pless than0.001. Minimal Disease Activity: In both studies, a significantly higher proportion of patients treated with bimekizumab achieved the ranked secondary endpoint of Minimal Disease Activity response, compared with placebo at week 16. In BE OPTIMAL, at week 16, 45.0 percent of biologic-naive patients treated with bimekizumab achieved MDA versus 13.2 percent on placebo; pless than0.001. In BE COMPLETE, at week 16, 44.2 percent of TNF-inadequate responder patients treated with bimekizumab achieved MDA versus 6.0 percent on placebo; pless than0.001. Additional Outcomes: In BE OPTIMAL, treatment with bimekizumab compared with placebo was associated with a statistically significant inhibition of progression of structural joint damage at week 16, as measured by mean change from baseline in the van der Heijde modified Total Sharp Score, a ranked secondary endpoint. The clinical response in both studies was rapid, with separation from placebo observed from week two in BE OPTIMAL and week four in BE COMPLETE. In BE OPTIMAL, response rates continued to improve to week 24: 45.5 percent of patients treated with bimekizumab achieved ACR50 and 35.9 percent of patients switching from placebo to bimekizumab at week 16 achieved ACR50, following an eight week treatment duration; 72.8 percent of bimekizumab-treated patients achieved PASI90 and 61.4 percent of patients switching from placebo to bimekizumab at week 16 achieved PASI90; 48.5 percent of patients treated with bimekizumab achieved MDA and 37.7 percent switching from placebo to bimekizumab at week 16 achieved MDA. An active reference arm of adalimumab was included in the BE OPTIMAL study. The study was not powered for statistical comparisons with the bimekizumab treatment group or placebo. At week 16, 45.7 percent, 41.2 percent and 45.0 percent of patients treated with adalimumab achieved ACR50, PASI90 and MDA, respectively In BE OPTIMAL, over 16 weeks, 59.9 percent of patients treated with bimekizumab had greater than or equal to one treatment emergent adverse event versus 49.5 percent of patients on placebo and 59.3 percent on adalimumab. The three most frequent TEAEs were nasopharyngitis, upper respiratory tract infection and increased alanine aminotransferase. Candida infections were reported in 2.6 percent of bimekizumab-treated patients, 0.7 percent on placebo and 0 percent on adalimumab. The incidence of serious adverse events was low: 1.6 percent of patients treated with bimekizumab versus 1.1 percent on placebo and 1.4 percent on adalimumab. No cases of systemic candidiasis, inflammatory bowel disease, major adverse cardiovascular events or uveitis were reported. In BE COMPLETE, over 16 weeks, 40.1 percent of patients treated with bimekizumab had greater than or equal to one TEAE versus 33.3 percent of patients on placebo.2 The three most frequent TEAEs for patients treated with bimekizumab were nasopharyngitis, oral candidiasis, and upper respiratory tract infection. Two patients on bimekizumab discontinued treatment due to a TEAE. The incidence of SAEs was low: 1.9 percent of patients treated with bimekizumab versus 0 percent on placebo, and none led to discontinuation. No cases of systemic candidiasis, IBD, MACE, venous thromboembolism, or uveitis were reported.

ShowHide Related Items >><<
UCBJY UCB
$45.89 /

-1.1 (-2.34%)

05/20/22 Berenberg
UCB price target lowered to EUR 120 from EUR 122 at Berenberg
05/19/22 Morgan Stanley
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
05/16/22 UBS
UCB price target lowered to EUR 95 from EUR 105 at UBS
03/03/22 Morgan Stanley
UCB upgraded to Overweight from Equal Weight at Morgan Stanley
Recommendations
UCB price target lowered to EUR 120 from EUR 122 at Berenberg » 14:55
05/20/22
05/20
14:55
05/20/22
14:55
UCBJY

UCB

$46.99 /

+0.74 (+1.60%)

Berenberg lowered the…

Berenberg lowered the firm's price target on UCB to EUR 120 from EUR 122 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
UCBJY UCB
$46.99 /

+0.74 (+1.60%)

05/19/22 Morgan Stanley
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
05/16/22 UBS
UCB price target lowered to EUR 95 from EUR 105 at UBS
03/03/22 Morgan Stanley
UCB upgraded to Overweight from Equal Weight at Morgan Stanley
01/24/22 Deutsche Bank
UCB downgraded to Hold from Buy at Deutsche Bank
Downgrade
UCB downgraded to Equal Weight from Overweight at Morgan Stanley » 06:18
05/19/22
05/19
06:18
05/19/22
06:18
UCBJY

UCB

$46.25 /

-0.54 (-1.15%)

Morgan Stanley analyst…

Morgan Stanley analyst Thibault Boutherin downgraded UCB to Equal Weight from Overweight with a price target of EUR 110, down from EUR 120. The analyst cites the delay of the U.S. Bimzelx launch for the downgrade. The analyst lowered his global peak sales estimate for the psoriasis treatment to EUR 2.6B from EUR 3B as he now expects a slower ramp-up and greater competition.

ShowHide Related Items >><<
UCBJY UCB
$46.25 /

-0.54 (-1.15%)

UCBJY UCB
$46.25 /

-0.54 (-1.15%)

05/16/22 UBS
UCB price target lowered to EUR 95 from EUR 105 at UBS
03/03/22 Morgan Stanley
UCB upgraded to Overweight from Equal Weight at Morgan Stanley
01/24/22 Deutsche Bank
UCB downgraded to Hold from Buy at Deutsche Bank
01/13/22 UBS
UCB downgraded to Sell from Buy at UBS
Recommendations
UCB price target lowered to EUR 95 from EUR 105 at UBS » 15:41
05/16/22
05/16
15:41
05/16/22
15:41
UCBJY

UCB

$45.71 /

-6.8425 (-13.02%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe lowered the firm's price target on UCB to EUR 95 from EUR 105 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
UCBJY UCB
$45.71 /

-6.8425 (-13.02%)

UCBJY UCB
$45.71 /

-6.8425 (-13.02%)

03/03/22 Morgan Stanley
UCB upgraded to Overweight from Equal Weight at Morgan Stanley
01/24/22 Deutsche Bank
UCB downgraded to Hold from Buy at Deutsche Bank
01/13/22 UBS
UCB downgraded to Sell from Buy at UBS
01/10/22 Citi
UCB downgraded to Neutral from Buy at Citi
Over a quarter ago
Upgrade
UCB upgraded to Overweight from Equal Weight at Morgan Stanley » 05:03
03/03/22
03/03
05:03
03/03/22
05:03
UCBJY

UCB

$54.95 /

-0.055 (-0.10%)

Morgan Stanley analyst…

Morgan Stanley analyst Thibault Boutherin upgraded UCB to Overweight from Equal Weight with a price target of EUR 120, up from EUR 100. The company's reiterated fiscal 2025 guidance removed "major uncertainties" and allows investors to "chart a growth path" over the medium term, Boutherin tells investors in a research note.

ShowHide Related Items >><<
UCBJY UCB
$54.95 /

-0.055 (-0.10%)

UCBJY UCB
$54.95 /

-0.055 (-0.10%)

01/24/22 Deutsche Bank
UCB downgraded to Hold from Buy at Deutsche Bank
01/13/22 UBS
UCB downgraded to Sell from Buy at UBS
01/10/22 Citi
UCB downgraded to Neutral from Buy at Citi
10/19/21 Barclays
UCB downgraded to Equal Weight from Overweight at Barclays
Downgrade
UCB downgraded to Hold from Buy at Deutsche Bank » 05:45
01/24/22
01/24
05:45
01/24/22
05:45
UCBJY

UCB

$51.30 /

-0.1 (-0.19%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis downgraded UCB to Hold from Buy with a price target of EUR 95, down from EUR 115. With rozanolixizumab/zilucoplan details more likely a second half of 2022 event and bimekizumab delayed, there are "few compelling reasons to stay explicitly constructive short term," Papadakis tells investors in a research note.

ShowHide Related Items >><<
UCBJY UCB
$51.30 /

-0.1 (-0.19%)

UCBJY UCB
$51.30 /

-0.1 (-0.19%)

01/13/22 UBS
UCB downgraded to Sell from Buy at UBS
01/10/22 Citi
UCB downgraded to Neutral from Buy at Citi
10/19/21 Barclays
UCB downgraded to Equal Weight from Overweight at Barclays
09/16/21 Jefferies
UCB upgraded to Buy from Hold at Jefferies
Downgrade
UCB downgraded to Sell from Buy at UBS » 05:33
01/13/22
01/13
05:33
01/13/22
05:33
UCBJY

UCB

$53.26 /

+0.02 (+0.04%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe double downgraded UCB to Sell from Buy with a price target of EUR 88, down from EUR 116. Quoting delays related to FDA approval for the company's potentially "biggest-ever drug," bimekizumab, makes ear-term consensus estimates look "much too high," Sutcliffe tells investors in a research note.

ShowHide Related Items >><<
UCBJY UCB
$53.26 /

+0.02 (+0.04%)

UCBJY UCB
$53.26 /

+0.02 (+0.04%)

01/10/22 Citi
UCB downgraded to Neutral from Buy at Citi
10/19/21 Barclays
UCB downgraded to Equal Weight from Overweight at Barclays
09/16/21 Jefferies
UCB upgraded to Buy from Hold at Jefferies
09/02/21 Barclays
UCB price target raised to EUR 102 from EUR 100 at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.